18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Mouse studies suggest FGF21 could help treat spinal cord damage associated with traumatic brain injury (TBI) and multiple sclerosis. In postmortem tissue samples from MS patients, levels of the FGF21 signaling marker klotho...
14:37 , Apr 28, 2017 |  BC Week In Review  |  Clinical News

BMS-986036: Additional Ph II data

Additional data from a double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 for 16 weeks...
02:34 , Apr 24, 2017 |  BC Extra  |  Clinical News

NGM, BMS add to NASH data

Newly released data from a Phase II study of NGM282 from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) to treat non-alcoholic steatohepatitis showed that 3 and 6 mg doses of the candidate increased LDL levels...
23:33 , Apr 14, 2017 |  BioCentury  |  Product Development

New endpoints in NASH

Data on mid-stage NASH candidates to be presented at the European Association for the Study of the Liver’s International Liver Congress this month won’t enable solid comparisons with each other or with more advanced programs....
19:18 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

BMS-986036: Ph II data

A double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 each met the primary endpoint of...
22:41 , Apr 5, 2017 |  BC Extra  |  Clinical News

New NASH readouts for NGM, Bristol

New data showed that fibroblast growth factor (FGF) analogs from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) and Bristol-Myers Squibb Co. (NYSE:BMY) each reduced liver fat in separate Phase II studies to treat non-alcoholic steatohepatitis....
22:05 , Jan 6, 2017 |  BC Week In Review  |  Company News

Ambrx, MabSpace deal

Ambrx and MabSpace partnered exclusively to discover and develop oncology antibody drug conjugates (ADCs). The partners will use MabSpace's humanized antibody technology in combination with Ambrx's EuCode conjugation platform. The partners said they will share...
03:51 , Nov 19, 2016 |  BioCentury  |  Strategy

Adding on in fibrosis

Bristol-Myers Squibb Co.’s deal to license worldwide rights to Nitto Denko Corp.’s antifibrotic siRNA therapy gives the pharma one of industry’s broadest fibrosis pipelines - and the ability to test multiple combinations. BMS now owns...
23:49 , Nov 10, 2016 |  BC Extra  |  Company News

BMS's NASH portfolio grows via deal for Nitto's siRNA

Nitto Denko Corp. (Tokyo:6988) granted Bristol-Myers Squibb Co. (NYSE:BMY) an exclusive, worldwide license to clinical candidate ND-L02-s0201 to treat liver diseases including non-alcoholic steatohepatitis (NASH). The companies' deal covers Nitto's molecules targeting serpin peptidase inhibitor...
07:00 , Sep 22, 2016 |  BC Innovations  |  Emerging Company Profile

Base instincts

Mark Zipkin, Staff Writer  Although unnatural amino acids can help synthetic biologists create improved versions of therapeutic proteins, they have been difficult to integrate into conventional E.coli-based manufacturing systems. Synthorx is adding two synthetic bases, dubbed...